BRPI0418373A - composição farmacêutica, unidade de dosagem de cci-779 oral, método de fornecimento de cci-779 a um paciente, e, uso de cci-779 micronizado - Google Patents

composição farmacêutica, unidade de dosagem de cci-779 oral, método de fornecimento de cci-779 a um paciente, e, uso de cci-779 micronizado

Info

Publication number
BRPI0418373A
BRPI0418373A BRPI0418373-8A BRPI0418373A BRPI0418373A BR PI0418373 A BRPI0418373 A BR PI0418373A BR PI0418373 A BRPI0418373 A BR PI0418373A BR PI0418373 A BRPI0418373 A BR PI0418373A
Authority
BR
Brazil
Prior art keywords
cci
patient
oral
pharmaceutical composition
dosage unit
Prior art date
Application number
BRPI0418373-8A
Other languages
English (en)
Inventor
Muhammad Ashraf
Eric J Benjamin
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of BRPI0418373A publication Critical patent/BRPI0418373A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Abstract

COMPOSIçãO FARMACêUTICA, UNIDADE DE DOSAGEM DE CCI-779 ORAL, MéTODO DE FORNECIMENTO DE CCI-779 A UM PACIENTE,E,USO DE CCI-779 MICRONIZADO é descrito CCI- 779, o éster rapamina-42 diretamente comprimível, com ácido 3-hidróxi-2-(hidroximetil)-2-metilpropiónico provê um método conveniente e eficaz para fornecer níveis terapêuticos de CCI-79 a um paciente.
BRPI0418373-8A 2004-01-08 2004-12-14 composição farmacêutica, unidade de dosagem de cci-779 oral, método de fornecimento de cci-779 a um paciente, e, uso de cci-779 micronizado BRPI0418373A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53495104P 2004-01-08 2004-01-08
PCT/US2004/042178 WO2005070393A2 (en) 2004-01-08 2004-12-14 Directly compressible pharmaceutical composition of the rapamycin ester cci-779

Publications (1)

Publication Number Publication Date
BRPI0418373A true BRPI0418373A (pt) 2007-05-22

Family

ID=34806893

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0418373-8A BRPI0418373A (pt) 2004-01-08 2004-12-14 composição farmacêutica, unidade de dosagem de cci-779 oral, método de fornecimento de cci-779 a um paciente, e, uso de cci-779 micronizado

Country Status (31)

Country Link
US (1) US20050152983A1 (pt)
EP (1) EP1701698B1 (pt)
JP (1) JP2007517879A (pt)
KR (1) KR20060130162A (pt)
CN (1) CN1921861A (pt)
AR (1) AR047180A1 (pt)
AT (1) ATE383859T1 (pt)
AU (1) AU2004314213A1 (pt)
BR (1) BRPI0418373A (pt)
CA (1) CA2552595A1 (pt)
CR (1) CR8491A (pt)
CY (1) CY1107373T1 (pt)
DE (1) DE602004011398T2 (pt)
DK (1) DK1701698T3 (pt)
EC (1) ECSP066757A (pt)
ES (1) ES2298861T3 (pt)
GT (1) GT200500003A (pt)
HK (1) HK1090308A1 (pt)
HN (1) HN2005000005A (pt)
IL (1) IL176519A0 (pt)
MX (1) MXPA06007829A (pt)
NO (1) NO20062930L (pt)
PA (1) PA8621201A1 (pt)
PE (1) PE20050683A1 (pt)
PL (1) PL1701698T3 (pt)
PT (1) PT1701698E (pt)
RU (1) RU2006122517A (pt)
TW (1) TW200526213A (pt)
UA (1) UA84903C2 (pt)
WO (1) WO2005070393A2 (pt)
ZA (1) ZA200605631B (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20060090803A (ko) 2003-09-03 2006-08-16 와이어쓰 3-하이드록시-2-(하이드록시메틸)-2-메틸프로피온산을 갖는무정형 라파마이신 42-에스테르 및 이를 함유하는약제학적 조성물
EP1737869A1 (en) * 2004-04-14 2007-01-03 Wyeth a Corporation of the State of Delaware Regiospecific synthesis of rapamycin 42-ester derivatives
BRPI0510277A (pt) * 2004-04-27 2007-10-30 Wyeth Corp método para marcar especificamente uma rapamicina, rapamicina especificamente marcada, composição, e, kit
CA2596392A1 (en) * 2005-02-15 2006-08-24 Wyeth Orally bioavailable cci-779 tablet formulations
CN102579467A (zh) 2005-11-14 2012-07-18 阿里亚德医药股份有限公司 雷帕霉素衍生物在治疗癌症中的用途
EP2040718B1 (en) * 2006-06-28 2017-12-27 Emisphere Technologies, Inc. Gallium nitrate formulations
US9700704B2 (en) 2006-11-20 2017-07-11 Lutonix, Inc. Drug releasing coatings for balloon catheters
US8414525B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8414526B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
US9737640B2 (en) 2006-11-20 2017-08-22 Lutonix, Inc. Drug releasing coatings for medical devices
US20080276935A1 (en) 2006-11-20 2008-11-13 Lixiao Wang Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
US20080175887A1 (en) 2006-11-20 2008-07-24 Lixiao Wang Treatment of Asthma and Chronic Obstructive Pulmonary Disease With Anti-proliferate and Anti-inflammatory Drugs
US8998846B2 (en) 2006-11-20 2015-04-07 Lutonix, Inc. Drug releasing coatings for balloon catheters
US8414910B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8425459B2 (en) 2006-11-20 2013-04-23 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
WO2010024898A2 (en) 2008-08-29 2010-03-04 Lutonix, Inc. Methods and apparatuses for coating balloon catheters
WO2011151704A2 (en) 2010-06-02 2011-12-08 Fresenius Kabi Oncology Ltd. Stable pharmaceutical compositions of rapamycin esters
MX342405B (es) 2010-06-03 2016-09-28 Pharmacyclics Inc El uso de inhibidores de la tirosina quinasa de bruton (btk).
KR20150015021A (ko) 2012-06-04 2015-02-09 파마시클릭스, 인코포레이티드 브루톤 타이로신 키나아제 저해제의 결정 형태
AU2013293087B2 (en) 2012-07-24 2017-08-31 Pharmacyclics Llc Mutations associated with resistance to inhibitors of Bruton's tyrosine kinase (BTK)
US10682415B2 (en) 2013-07-22 2020-06-16 Wisconsin Alumni Research Foundation Thermogel formulation for combination drug delivery
CN104721158B (zh) * 2013-12-24 2018-01-30 正大天晴药业集团股份有限公司 一种稳定的依维莫司片剂
RU2017133990A (ru) 2015-03-03 2019-04-05 Фармасайкликс Элэлси Фармацевтические лекарственные формы ингибитора тирозинкиназы брутона
JP6793652B2 (ja) * 2015-09-03 2020-12-02 日本化薬株式会社 ラパマイシン又はその誘導体を含有する医薬組成物
WO2017129772A1 (en) 2016-01-29 2017-08-03 Xellia Phamaceuticals Aps Stable pharmaceutical compositions of temsirolimus

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA737247B (en) * 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
JP2642486B2 (ja) * 1989-08-04 1997-08-20 田辺製薬株式会社 難溶性薬物の超微粒子化法
US5536729A (en) * 1993-09-30 1996-07-16 American Home Products Corporation Rapamycin formulations for oral administration
US5928668A (en) * 1993-12-21 1999-07-27 Applied Analytical Industries, Inc. Method for dry blend compression of medicaments
US5362718A (en) * 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
FR2736550B1 (fr) * 1995-07-14 1998-07-24 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule
EP0925061B1 (en) * 1996-08-22 2005-12-28 Jagotec Ag Compositions comprising microparticles of water-insoluble substances and method for preparing same
US5989591A (en) * 1997-03-14 1999-11-23 American Home Products Corporation Rapamycin formulations for oral administration
US5985325A (en) * 1997-06-13 1999-11-16 American Home Products Corporation Rapamycin formulations for oral administration
US6277983B1 (en) * 2000-09-27 2001-08-21 American Home Products Corporation Regioselective synthesis of rapamycin derivatives
TWI286074B (en) * 2000-11-15 2007-09-01 Wyeth Corp Pharmaceutical composition containing CCI-779 as an antineoplastic agent
UA77200C2 (en) * 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569
BR0314397A (pt) * 2002-09-17 2005-08-09 Wyeth Corp Formulações orais
UA83484C2 (uk) * 2003-03-05 2008-07-25 Уайт Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція
EP1648454A1 (en) * 2003-07-25 2006-04-26 Wyeth Cci-779 lyophilized formulations
ATE365169T1 (de) * 2003-08-07 2007-07-15 Wyeth Corp Regioselektive synthese von cci-779
KR20060090803A (ko) * 2003-09-03 2006-08-16 와이어쓰 3-하이드록시-2-(하이드록시메틸)-2-메틸프로피온산을 갖는무정형 라파마이신 42-에스테르 및 이를 함유하는약제학적 조성물
US20060142422A1 (en) * 2004-12-07 2006-06-29 Toshikazu Kobayashi Hydrolysis resistant polyester compositions and articles made therefrom
CA2596392A1 (en) * 2005-02-15 2006-08-24 Wyeth Orally bioavailable cci-779 tablet formulations

Also Published As

Publication number Publication date
US20050152983A1 (en) 2005-07-14
WO2005070393A3 (en) 2006-09-28
PA8621201A1 (es) 2005-12-23
PT1701698E (pt) 2008-03-27
NO20062930L (no) 2006-10-02
AU2004314213A1 (en) 2005-08-04
GT200500003A (es) 2005-08-18
CR8491A (es) 2008-08-21
KR20060130162A (ko) 2006-12-18
TW200526213A (en) 2005-08-16
ATE383859T1 (de) 2008-02-15
ZA200605631B (en) 2010-01-27
CA2552595A1 (en) 2005-08-04
CY1107373T1 (el) 2012-12-19
PL1701698T3 (pl) 2008-03-31
DK1701698T3 (da) 2008-05-05
DE602004011398T2 (de) 2009-01-15
RU2006122517A (ru) 2008-02-20
DE602004011398D1 (de) 2008-03-06
HN2005000005A (es) 2009-04-17
JP2007517879A (ja) 2007-07-05
AR047180A1 (es) 2006-01-11
ES2298861T3 (es) 2008-05-16
EP1701698A2 (en) 2006-09-20
EP1701698B1 (en) 2008-01-16
HK1090308A1 (en) 2006-12-22
MXPA06007829A (es) 2006-09-01
ECSP066757A (es) 2006-11-16
CN1921861A (zh) 2007-02-28
UA84903C2 (ru) 2008-12-10
IL176519A0 (en) 2006-10-05
WO2005070393A2 (en) 2005-08-04
PE20050683A1 (es) 2005-11-04

Similar Documents

Publication Publication Date Title
BRPI0418373A (pt) composição farmacêutica, unidade de dosagem de cci-779 oral, método de fornecimento de cci-779 a um paciente, e, uso de cci-779 micronizado
UY27740A1 (es) Nuevos compuestos
BRPI0707235B8 (pt) formulação de fentanil sublingual sem propelente, e, dispositivo de dose unitária para administração sublingual de uma formulação de fentanil sublingual
EA200701131A1 (ru) Гелеобразная препаративная форма капсаициноида и способы её применения
GB0420888D0 (en) Compounds and uses
BRPI1007945B8 (pt) formulação farmacêutica de liberação controlada de nitazoxamida, tizoxanida ou uma combinação dos mesmos, e, comprimido de bicamada para administração oral
NO20065878L (no) Terapeutiske forbindelser
AR045972A1 (es) Formulaciones de tramadol de liberacion sostenida con eficacia de 24 horas
BR0311931A (pt) Composto, composição farmacêutica, uso de um composto, e, método para tratar uma doença ou condição mediada com hppar em um paciente
ATE543491T1 (de) Kombinationspräparat enthaltend ibuprofen und paracetamol
CL2011002858A1 (es) Uso de una composicion farmaceutica transmucosa oral que comprende dexmedetomidina y una sal farmaceuticamente aceptable y un excipiente farmaceuticamente aceptable para preparar un medicamento util para tratar o prevenir el dolor.
CL2011002248A1 (es) Composicion farmaceutica oral de liberacion inmediata que comprende oxicodona y naloxona en una proporcion 2:1 en peso; uso de la composicion farmaceutica para tratar dolor intercurrente en paciente que sufren de dolor.
SE0401342D0 (sv) Therapeutic compounds
BR0315580A (pt) Derivados de metileno uréia
UY29818A1 (es) Nuevos compuestos de azetidina, composiciones farmaceuticas que los contienen, procesos de preparacion y sus usos terapeuticos
MX2009004017A (es) Usos de los compuestos carboxi-amido triazol y sus sales.
NZ587202A (en) Methods for measuring a patient response upon administration of a drug and compositions thereof
AR063782A1 (es) Parche y metodo transdermico para emesis
BR112013010829B8 (pt) Composição farmacêutica intravenosa para proporcionar alívio da dor e/ou da inflamação
PE20040068A1 (es) Decanoato, undecanoato y dodecanoato de etonogestrel
MX2021014774A (es) Formulaciones de liberacion modificada y usos de las mismas.
CL2010001577A1 (es) Uso de nifurtimox para preparar un medicamento util en el tratamiento de enfermedades causadas por giardias.
ATE500263T1 (de) Neue 2',3'-methylidenacetyladenosine prodrugs zur verwendung als adenosinrezeptoragonisten
BR0108313A (pt) Composição farmacêutica para injeção intramuscular contendo loxoprofeno
BRPI0519006A2 (pt) uso de um inibidor de fbpase, kit de uma composiÇço farmacÊutica, uso de uma preparaÇço de biguanida e um inibidor de fbpase, agente terapÊutico para diabetes melito, e, combinaÇço de agentes terapÊuticos

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA: INT. CL. A61K 31/4745, 9/20, 9/48; A61P 35/00

Ipc: A61K 31/4745 (2011.01), A61K 9/20 (2011.01), A61K

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.